Cartalax Peptide Guide: Research Reference and Reported Protocols

Overview

Cartalax is an investigational peptide bioregulator of the Khavinson type — a short synthetic peptide derived from the cartilage-tissue sequence, developed in Russian research. This reference guide collects what the published literature reports, how concentration arithmetic works for a vial, and how to verify that material actually contains what its label claims. It does not describe how to administer Cartalax, and Cartalax is not approved for human use by any regulator. For concentration and dilution math, see our Cartalax calculator →

What Cartalax is and where the research comes from

The Khavinson peptide bioregulators are a family of short synthetic peptides, each derived from a tissue-specific protein sequence, developed in Russian research starting in the 1970s. Cartalax is the member associated with cartilage and connective tissue. The underlying concept is "peptide regulation of gene expression" — the proposition that short peptides can influence transcription in the tissue they were derived from, rather than acting through a receptor in the way a conventional drug does.

That concept is the claim the literature rests on, and it is worth stating clearly because it shapes how the evidence should be read. The mechanistic hypothesis is unusual by the standards of Western pharmacology, the primary literature is concentrated in Russian-language publications, and independent replication in English-language journals is limited. None of that makes the research worthless — but it does mean a reader should know what kind of literature they are reading.

What the research literature reports

The table below reproduces amounts as reported in published studies, for reference. Different studies used different routes and preparations, and the figures are not interchangeable across them.

Route studied	Amount reported in studies	Interval studied	Research context
Intramuscular (research use)	10 mg	daily, short courses	Peptide-bioregulator protocols
Oral/sublingual capsule	10 mg	daily	Commercially available form
In-vitro cell culture	micromolar range	continuous exposure	Cartilage-cell and gene-expression work

These are study parameters administered under protocol supervision. They are not a regimen to follow, and reproducing a published figure carries no implication that it is appropriate for any particular use.

Reported mechanisms

The mechanisms proposed in the literature, and the type of evidence behind each:

• Tissue-specific gene expression — the core hypothesis; supported mainly by in-vitro work
• Cartilage-cell proliferation and matrix synthesis — in-vitro and some animal-model studies
• Anti-inflammatory activity in joint models — animal-model work
• Connective-tissue repair — the endpoint most often asserted, with the least direct human evidence

Each of those is a mechanistic or animal-model finding. The gap between a mechanism demonstrated in culture and an outcome observed in a person is the widest gap in this field, and summaries that skip it are not informative.

Safety considerations

Safety data for the peptide-bioregulator family comes predominantly from animal studies and from the fact that these compounds are sold as oral supplements in some markets, which establishes a history of use but not a formal safety evaluation. Neither source identifies rare events, interactions, or effects in pregnancy.

Anyone assessing Cartalax should hold four facts together: there is no approved product, no regulator has evaluated it, the human clinical evidence base is very thin, and material sold under a research label may not contain what the label claims. The uncertainty here is high and largely irreducible from the outside.

Verifying what is in a vial

A calculator assumes the label is accurate. Independent verification is a separate step:

• HPLC purity testing — establishes what proportion of the material is the target peptide
• Mass spectrometry — confirms molecular identity; short bioregulator peptides are difficult to distinguish from related fragments by other means
• Amino-acid sequence confirmation — confirms which member of the bioregulator family the material actually is; the family members differ only slightly
• Batch-matched certificate of analysis — ties the result to the specific lot you hold; a COA for another lot proves nothing about yours

Our vendor pages record which suppliers publish batch-level COAs, and the forum collects community testing results — including failed tests — alongside supplier discussion. Across research peptides generally, mislabelled or absent material is common enough that an unverified label should be treated as a claim rather than a fact. For a family whose members differ by a few residues, sequence confirmation matters more than a headline purity percentage.

Handling and storage conventions

Unreconstituted (lyophilised) material is generally stable at ambient temperature for the duration of normal shipping and is typically stored frozen for longer-term stability. Once a diluent is added, the solution is usually refrigerated and used within a defined window, because the reconstituted state is less stable than the powder. These are handling conventions rather than arithmetic — verify them against the supplier's own documentation.

What the research shows, and what it does not

The honest summary of the Cartalax literature: there is a substantial Russian-language research tradition around peptide bioregulators, in-vitro and animal-model evidence for effects on cartilage-cell activity, and a mechanistic hypothesis about tissue-specific gene expression that remains outside mainstream pharmacology. What does not exist is a body of well-powered human clinical trials, an approved product, or a regulatory assessment.

Where we summarise this research, we cite the study type so a reader can separate an in-vitro result from an animal-model result from a clinical one. That distinction is the single most useful thing to carry into reading any peptide research, and it is the one most summaries omit.

Related Peptides

Frequently Asked Questions

Related Guides